PPM1A is a RelA phosphatase with tumor suppressor-like activity

Oncogene

Volumn 33, Issue 22, 2014, Pages 2918-2927

  Lu, X ^a   An, H ^a,b   Jin, R ^b   Zou, M ^c   Guo, Y ^a   Su, P F ^b   Liu, D ^c   Shyr, Y ^b   Yarbrough, W G ^c,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE CANCER CENTER   (United States)

Author keywords

NF B; phosphatase; PPM1A; prostate cancer; tumor suppressor

Indexed keywords

INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOPROTEIN PHOSPHATASE 2; PHOSPHOPROTEIN PHOSPHATASE 2C; PROTEIN PPM1A; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME ACTIVITY; GENE DELETION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; MOUSE MODEL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN DEPHOSPHORYLATION; PROTEIN DNA BINDING; PROTEIN FUNCTION; SENSITIZATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HETEROGRAFTS; HUMANS; MALE; MICE; NEOPLASM METASTASIS; NF-KAPPA B; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

EID: 84901834334     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.246     Document Type: Article

References (56)

1. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010; 20: 65-71.
2. Orlowski RZ, Baldwin J, Albert S. NF-[kappa]B as a therapeutic target in cancer. Trends Mol Med 2002; 8: 385-389.
3. Wang J, An H, Mayo MW, Baldwin AS, WG Yarbrough. LZAP a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 2007; 12: 239-251. (Pubitemid 47333414)
4. Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C. Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 2009; 15: 5974-5984.
5. Cao Y, Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003; 8: 215-223. (Pubitemid 38129943)
6. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005; 123: 158-169. (Pubitemid 40094658)
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366-381. (Pubitemid 36886244)
9. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286-294.
10. Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 2010; 95: 31-53.
11. Craig MJ, Loberg RD. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev 2006; 25: 611-619. (Pubitemid 46071867)
12. Chen L-F, Green WC. Shaping the nuclear action of NF-kB. Nat Rev Mol Cell Biol 2004; 5: 392-401.
13. Neumann M, Naumann M. Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J 2007; 21: 2642-2654. (Pubitemid 47372732)
14. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, Chino A et al. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 2003; 278: 36916-36923. (Pubitemid 37140026)
15. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002; 9: 625-636. (Pubitemid 34273792)
16. Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 2004; 306: 704-708. (Pubitemid 39440922)
17. Yang J, Fan GH, Wadzinski BE, Sakurai H, Richmond A. Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem 2001; 276: 47828-47833.
18. Chew J, Biswas S, Shreeram S, Humaidi M, Wong ET, Dhillion MK et al. WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat Cell Biol 2009; 11: 659-666.
19. Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell 2006; 125: 915-928. (Pubitemid 43795197)
20. Lammers T, Lavi S. Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling. Crit Rev Biochem Mol Biol 2007; 42: 437-461. (Pubitemid 350232897)
21. Shohat M, Ben-Meir D, Lavi S. Protein phosphatase magnesium dependent 1A (PPM1A) plays a role in the differentiation and survival processes of nerve cells. PLoS ONE 2012; 7: e32438.
22. Zhang B, Zhou Z, Lin H, Lv X, Fu J, Lin P et al. Protein phosphatase 1A (PPM1A) is involved in human cytotrophoblast cell invasion and migration. Histochem Cell Biol 2009; 132: 169-179.
23. Sun W, Yu Y, Dotti G, Shen T, Tan X, Savoldo B et al. PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation. Cell Signal 2009; 21: 95-102.
24. Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K et al. Phosphor-ylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem 2004; 279: 49571-49574. (Pubitemid 39577758)
25. Schwabe RF, Sakurai H. IKKbeta phosphorylates p65 at S468 in transactivaton domain 2. FASEB J 2005; 19: 1758-1760. (Pubitemid 41429554)
26. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006; 25: 6717-6730. (Pubitemid 44657848)
27. Kim JS, Rho B, Lee TH, Lee JM, Kim SJ, Park JH. The interaction of hepatitis B virus X protein and protein phosphatase type 2 Calpha and its effect on IL-6. Biochem Biophys Res Commun 2006; 351: 253-258. (Pubitemid 44635434)
28. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga K et al. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994; 153: 2052-2063.
29. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J Biol Chem 1997; 272: 31092-31099. (Pubitemid 27527558)
30. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8: 837-848.
31. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009; 1: a000034.
32. Wang CY, Mayo MW, Baldwin Jr AS. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-787. (Pubitemid 26398259)
33. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-225.
34. Zhang J, Patel L, Pienta KJCC. chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010; 21: 41-48.
35. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006; 66: 1311-1318. (Pubitemid 44384308)
36. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7: 64.
37. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790-2799. (Pubitemid 41079896)
38. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998; 77: 887-894. (Pubitemid 28378138)
39. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109(Suppl 1): S81-S96.
40. Gardam S, Beyaert R. The kinase NIK as a therapeutic target in multiple myeloma. Expert Opin Ther Targets 2011; 15: 207-218.
41. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011; 30: 1615-1630.
42. Yamaguchi H, Durell SR, Chatterjee DK, Anderson CW, Appella E. The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. Biochemistry 2007; 46: 12594-12603. (Pubitemid 350064221)
43. Yamaguchi H, Minopoli G, Demidov ON, Chatterjee DK, Anderson CW, Durell SR et al. Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. Biochemistry 2005; 44: 5285-5294. (Pubitemid 40489968)
44. Browning DD, Pan ZK, Prossnitz ER, Ye RD. Cell type-and developmental stage-specific activation of NF-kappaB by fMet-Leu-Phe in myeloid cells. J Biol Chem 1997; 272: 7995-8001. (Pubitemid 27137363)
45. Smale ST. Hierarchies of NF-kappaB target-gene regulation. Nat Immunol 2011; 12: 689-694.
46. Azevedo A, Cunha V, Teixeira AL, Medeiros R. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2011; 2: 384-396.
47. Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 2012; 22: 91-105.
48. Mueller L, Seggern LV, Schumacher J, Goumas F, Wilms C, Braun F et al. TNF-alpha similarly induces IL-6 and MCP-1 in fibroblasts from colorectal liver metastases and normal liver fibroblasts. Biochem Biophys Res Commun 2010; 397: 586-591.
49. Sosnoski DM, Krishnan V, Kraemer WJ, Dunn-Lewis C, Mastro AM. Changes in cytokines of the bone microenvironment during breast cancer metastasis. Int J Breast Cancer 2012; 2012: 160265.
50. Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis 2012; 29: 585-601.
51. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17: 6083-6096.
52. Lammers T, Peschke P, Ehemann V, Debus J, Slobodin B, Lavi S et al. Role of PP2Calpha in cell growth, in radio-and chemosensitivity, and in tumorigenicity. Mol Cancer 2007; 6: 65.
53. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007; 12: 342-354. (Pubitemid 47539308)
54. An H, Lu X, Liu D, Yarbrough WG. LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating p38 association with the wild-type p53 induced phosphatase 1 (WIP1). PLoS ONE 2011; 6: e16427.
55. Abdelmohsen K, Pullmann Jr R, Lal A, Kim HH, Galban S, Yang X et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 2007; 25: 543-557. (Pubitemid 46274441)
56. Drake JM, Gabriel CL, Henry MD. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis 2005; 22: 674-684. (Pubitemid 44259528)